Switch theme
Sign up to access all valuation multiples
Vaxcell-Bio Therapeutics is a bio-technology company engaged in the development of Cell-based and Protein-based Immunotherapeutics for the treatment of cancer.
2010
n/a
Last FY Revenue $1.4M
Last FY EBITDA -$6.5M
$139M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Vaxcell-Bio achieved revenue of $1.4M and an EBITDA of -$6.5M.
Vaxcell-Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vaxcell-Bio valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 19% | XXX | XXX | XXX |
| EBITDA | XXX | -$6.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -470% | XXX | XXX | XXX |
| EBIT | XXX | -$10.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | -792% | XXX | XXX | XXX |
| Net Profit | XXX | -$7.7M | XXX | XXX | XXX |
| Net Margin | XXX | -559% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vaxcell-Bio's stock price is KRW 9600 (or $7).
Vaxcell-Bio has current market cap of KRW 220B (or $160M), and EV of KRW 191B (or $139M).
See Vaxcell-Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $139M | $160M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vaxcell-Bio has market cap of $160M and EV of $139M.
Vaxcell-Bio's trades at 100.6x EV/Revenue multiple, and -21.4x EV/EBITDA.
Equity research analysts estimate Vaxcell-Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vaxcell-Bio's P/E ratio is not available.
See valuation multiples for Vaxcell-Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $160M | XXX | $160M | XXX | XXX | XXX |
| EV (current) | $139M | XXX | $139M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 100.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -21.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -12.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -20.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVaxcell-Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Vaxcell-Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vaxcell-Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vaxcell-Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -470% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 108% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 318% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 811% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vaxcell-Bio acquired XXX companies to date.
Last acquisition by Vaxcell-Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Vaxcell-Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vaxcell-Bio founded? | Vaxcell-Bio was founded in 2010. |
| Where is Vaxcell-Bio headquartered? | Vaxcell-Bio is headquartered in South Korea. |
| Who is the CEO of Vaxcell-Bio? | Vaxcell-Bio's CEO is Mr. Je-jung Lee. |
| Is Vaxcell-Bio publicy listed? | Yes, Vaxcell-Bio is a public company listed on KRX. |
| What is the stock symbol of Vaxcell-Bio? | Vaxcell-Bio trades under 323990 ticker. |
| When did Vaxcell-Bio go public? | Vaxcell-Bio went public in 2020. |
| Who are competitors of Vaxcell-Bio? | Similar companies to Vaxcell-Bio include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Vaxcell-Bio? | Vaxcell-Bio's current market cap is $160M |
| Is Vaxcell-Bio profitable? | Yes, Vaxcell-Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
